| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/CID/CIU581 |
| P698 | PubMed publication ID | 25048847 |
| P2093 | author name string | José Miguel Cisneros | |
| Ildefonso Espigado | |||
| Almudena Martín-Peña | |||
| Manuela Aguilar-Guisado | |||
| P2860 | cites work | The role of combination antifungal therapy in the treatment of invasive aspergillosis: a systematic review | Q27021187 |
| Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 | ||
| Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America | Q28263689 | ||
| Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial) | Q28298468 | ||
| Antifungal therapy in European hospitals: data from the ESAC point-prevalence surveys 2008 and 2009. | Q34349913 | ||
| Efficacy of micafungin alone or in combination against systemic murine aspergillosis | Q34884594 | ||
| Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients | Q35799730 | ||
| Combination therapy for invasive mycoses: evaluation of past clinical trial designs | Q35951634 | ||
| Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality | Q36715387 | ||
| Clinical practice: combination antifungal therapy for mold infections: much ado about nothing? | Q37157881 | ||
| Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin | Q37190801 | ||
| Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis | Q37204192 | ||
| Cost-effectiveness analysis comparing two approaches for empirical antifungal therapy in hematological patients with persistent febrile neutropenia | Q37263911 | ||
| Treatment cost of invasive fungal disease (Ifd) in patients with acute myelogenous leukaemia (Aml) or myelodysplastic syndrome (Mds) in German hospitals. | Q37999387 | ||
| Combination antifungal therapy for invasive fungal infections in children and adults | Q38102782 | ||
| Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis | Q39652561 | ||
| Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis | Q40667866 | ||
| Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. | Q42286250 | ||
| Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients? | Q42954068 | ||
| Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach. | Q43501661 | ||
| Combined therapy of voriconazole and anidulafungin in murine infections by Aspergillus flavus | Q44619968 | ||
| Guidelines for the treatment of invasive fungal disease by Aspergillus spp. and other fungi issued by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2011 Update | Q44731672 | ||
| Combination antifungal therapy for invasive aspergillosis | Q45096994 | ||
| Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis | Q46448567 | ||
| Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin | Q46840248 | ||
| Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study | Q46943408 | ||
| Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). | Q46946844 | ||
| Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis | Q46979014 | ||
| Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. | Q51187346 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | aspergillosis | Q259626 |
| P304 | page(s) | 1437-1445 | |
| P577 | publication date | 2014-07-21 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Antifungal combination therapy for invasive aspergillosis | |
| P478 | volume | 59 |
| Q40617936 | Administration of Zinc Chelators Improves Survival of Mice Infected with Aspergillus fumigatus both in Monotherapy and in Combination with Caspofungin |
| Q37103519 | Combination Antifungal Therapy for Invasive Aspergillosis Revisited. |
| Q34549917 | Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain |
| Q47548230 | Cryptococcus: Shedding New Light on an Inveterate Yeast |
| Q39732351 | Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection |
| Q90577176 | Extrapolating Antifungal Animal Data to Humans - Is it reliable? |
| Q30235457 | Intensive care medicine research agenda on invasive fungal infection in critically ill patients |
| Q42377766 | Invasive fungal infection (IFI) in pediatric leukemia: better outcome with ACT. |
| Q34532546 | Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America |
| Q39303919 | Successful Antifungal Combination Therapy and Surgical Approach for Aspergillus fumigatus Suppurative Thyroiditis Associated with Thyrotoxicosis and Review of Published Reports |
| Q40173835 | The Aspergillus fumigatus CrzA Transcription Factor Activates Chitin Synthase Gene Expression during the Caspofungin Paradoxical Effect. |
| Q40674435 | Use of intravoxel incoherent motion diffusion-weighted MR imaging for assessment of treatment response to invasive fungal infection in the lung |
Search more.